Alza Challenges Antitrust Claims In Ditropan Case

Law360, New York (June 21, 2007, 12:00 AM EDT) -- Alza Corp. has shot back at allegations raised by a purported class of indirect purchasers who claim that the Johnson & Johnson subsidiary violated federal and California antitrust laws by trying to keep generic versions of its bladder treatment Ditropan XL off the U.S. market.

Just days after Alza moved to dismiss the direct purchasers’ antitrust case against it, the Mountain View, Calif.-based company on Thursday contended that the purported class action by indirect purchasers should also be thrown out by the U.S. District Court for...
To view the full article, register now.